Amit Panwalkar

3.1k total citations · 1 hit paper
29 papers, 2.0k citations indexed

About

Amit Panwalkar is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Amit Panwalkar has authored 29 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 7 papers in Genetics. Recurrent topics in Amit Panwalkar's work include Lung Cancer Treatments and Mutations (10 papers), Lung Cancer Diagnosis and Treatment (9 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Amit Panwalkar is often cited by papers focused on Lung Cancer Treatments and Mutations (10 papers), Lung Cancer Diagnosis and Treatment (9 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Amit Panwalkar collaborates with scholars based in United States, Taiwan and Italy. Amit Panwalkar's co-authors include Srđan Verstovšek, Lecia V. Sequist, Ryan D. Gentzler, Hossein Borghaei, Mark M. Awad, Amita Patnaik, Shadia I. Jalal, Matthew A. Gubens, Shirish M. Gadgeel and James Chih‐Hsin Yang and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Amit Panwalkar

27 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

2016 1.1k citations Corey J. Langer, Shirish M. Gadgeel et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Amit Panwalkar United States	13	1.5k	1.0k	338	338	229	29	2.0k
Ryan D. Gentzler United States	20	2.1k 1.3×	1.4k 1.4×	285 0.8×	426 1.3×	219 1.0×	86	2.5k
Harry Raftopoulos United States	16	1.5k 1.0×	1.1k 1.1×	264 0.8×	330 1.0×	187 0.8×	40	2.4k
Andrew Dean Australia	17	1.1k 0.7×	694 0.7×	262 0.8×	124 0.4×	267 1.2×	104	1.6k
Alain Gelibter Italy	22	974 0.6×	574 0.6×	332 1.0×	127 0.4×	333 1.5×	100	1.4k
Jayaprakash Madhavan India	19	863 0.6×	1.1k 1.0×	456 1.3×	88 0.3×	197 0.9×	40	1.9k
Giulia Pasello Italy	23	1.1k 0.7×	1.1k 1.1×	510 1.5×	155 0.5×	349 1.5×	165	2.0k
Maen Hussein United States	15	2.5k 1.7×	1.7k 1.6×	249 0.7×	642 1.9×	224 1.0×	46	2.9k
Louise C. Connell United States	8	1.2k 0.8×	347 0.3×	242 0.7×	376 1.1×	107 0.5×	31	1.6k
Sebastiano Buti Italy	26	1.1k 0.7×	1.2k 1.2×	690 2.0×	275 0.8×	485 2.1×	210	2.2k
Steven Attia United States	23	1.0k 0.7×	1.4k 1.4×	369 1.1×	172 0.5×	154 0.7×	140	2.1k

Countries citing papers authored by Amit Panwalkar

Since Specialization

Citations

This map shows the geographic impact of Amit Panwalkar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amit Panwalkar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amit Panwalkar more than expected).

Fields of papers citing papers by Amit Panwalkar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amit Panwalkar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amit Panwalkar. The network helps show where Amit Panwalkar may publish in the future.

Co-authorship network of co-authors of Amit Panwalkar

This figure shows the co-authorship network connecting the top 25 collaborators of Amit Panwalkar. A scholar is included among the top collaborators of Amit Panwalkar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amit Panwalkar. Amit Panwalkar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Awad, Mark M., Shirish M. Gadgeel, Hossein Borghaei, et al.. (2021). OFP01.02 KEYNOTE-021 Cohort G Long-Term Follow-up: First-Line (1L) Pemetrexed and Carboplatin (PC) with or without Pembrolizumab for Advanced Nonsquamous NSCLC. Journal of Thoracic Oncology. 16(1). S8–S8. 1 indexed citations

Awad, Mark M., Shirish M. Gadgeel, Hossein Borghaei, et al.. (2020). Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC. Journal of Thoracic Oncology. 16(1). 162–168. 111 indexed citations

Borghaei, Hossein, Corey J. Langer, Shirish M. Gadgeel, et al.. (2018). 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer. Journal of Thoracic Oncology. 14(1). 124–129. 169 indexed citations

Langer, Corey J., Shirish M. Gadgeel, Hossein Borghaei, et al.. (2017). MA09.02 Pembrolizumab + Carboplatin and Pemetrexed as 1st-Line Therapy for Advanced Non–Small Cell Lung Cancer: KEYNOTE-021 Cohort G. Journal of Thoracic Oncology. 12(1). S391–S392. 1 indexed citations

Borghaei, Hossein, Corey J. Langer, Shirish M. Gadgeel, et al.. (2017). Updated results from KEYNOTE-021 cohort G: A randomized, phase 2 study of pemetrexed and carboplatin (PC) with or without pembrolizumab (pembro) as first-line therapy for advanced nonsquamous NSCLC. Annals of Oncology. 28. v636–v637. 19 indexed citations

Borghaei, Hossein, Corey J. Langer, Shirish M. Gadgeel, et al.. (2017). OA 17.01 Pemetrexed-Carboplatin Plus Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC: KEYNOTE-021 Cohort G Update. Journal of Thoracic Oncology. 12(11). S1791–S1791. 9 indexed citations

Langer, Corey J., Hossein Borghaei, Vassiliki A. Papadimitrakopoulou, et al.. (2016). Randomized, phase 2 study of carboplatin and pemetrexed with or without pembrolizumab as first-line therapy for advanced NSCLC: KEYNOTE-021 cohort G. Annals of Oncology. 27. vi582–vi582. 8 indexed citations

Langer, Corey J., Shirish M. Gadgeel, Hossein Borghaei, et al.. (2016). Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. The Lancet Oncology. 17(11). 1497–1508. 1071 indexed citations breakdown →

Gladstone, Douglas E., Marc André, Jan Maciej Zaucha, et al.. (2014). Phase 2 open-label study of MEDI-551 and bendamustine versus rituximab and bendamustine in adults with relapsed or refractory CLL.. Journal of Clinical Oncology. 32(15_suppl). 3028–3028. 3 indexed citations

10.

Panwalkar, Amit, et al.. (2008). 331: Effect of Smoking on Mobilization of Hematopoietic Stem Cells in Healthy Donors. Biology of Blood and Marrow Transplantation. 14(2). 122–122.

11.

Vose, Julie M., Amit Panwalkar, Robert Bélanger, et al.. (2007). A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myeloma. Leukemia & lymphoma. 48(1). 39–45. 6 indexed citations

12.

Panwalkar, Amit & Jamés O. Armitage. (2006). T-cell/NK-cell lymphomas: A review. Cancer Letters. 253(1). 1–13. 7 indexed citations

13.

Shonka, Nicole, James R. Anderson, Amit Panwalkar, et al.. (2006). Effect of Diabetes Mellitus on the Epidemiology and Outcomes of Colon Cancer. Medical Oncology. 23(4). 515–520. 25 indexed citations

14.

Panwalkar, Amit, Srđan Verstovšek, & Francis J. Giles. (2004). Nuclear factor‐KappaB modulation as a therapeutic approach in hematologic malignancies. Cancer. 100(8). 1578–1589. 81 indexed citations

15.

Panwalkar, Amit, Srđan Verstovšek, & Francis J. Giles. (2004). Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer. 100(4). 657–666. 179 indexed citations

16.

Potti, Anil, et al.. (2004). Role of HER-2/neu Overexpression and Clinical Features at Presentation as Predictive Factors in Meningiomas. American Journal of Clinical Oncology. 27(5). 452–456. 17 indexed citations

17.

Howe, Christopher, et al.. (2003). A Model for Clinical Estimation of Perioperative Hemorrhage. Clinical and Applied Thrombosis/Hemostasis. 9(2). 131–135. 23 indexed citations

18.

Potti, Anil, et al.. (2003). Prevalence of pesticide exposure in young males (. Journal of Carcinogenesis. 2(1). 4–4. 22 indexed citations

19.

Potti, Anil, et al.. (2003). An indolent B-cell lymphoma with t(2;8)(p12;q24) abnormality and absence of C-MYC amplification and TP53 deletion. A new variant?. Cancer Genetics and Cytogenetics. 144(1). 76–79. 2 indexed citations

20.

Potti, Anil, et al.. (2003). Ineffectiveness of Measuring Routine Vital Signs in Adult Inpatients With Deep Venous Thrombosis. Clinical and Applied Thrombosis/Hemostasis. 9(2). 163–166. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact